newsfilter
← Latest News
GlobeNewswire·

Evaxion receives International Prix Galien Award for AI-Immunology™ as best digital health solution

  • Evaxion A/S received the 2026 International Prix Galien Award for AI-Immunology™ as the best digital health solution.
  • This marks the first time a Danish company has won this prestigious international award.
  • Evaxion CEO Helen Tayton-Martin and founder/Chief AI Officer Andreas Holm Mattsson accepted the award at the American Museum of Natural History in New York City.
  • The AI-Immunology™ platform is a proprietary, clinically validated system used to decode the human immune system for developing immunotherapies against cancer, infectious diseases, and autoimmune conditions.
  • The company's furthest developed candidate, personalized cancer vaccine EVX-01, recently presented three-year phase 2 data showing durable outcomes in advanced melanoma patients.
  • Evaxion previously won the Prix Galien UK Award in June 2026 and a regional award in December 2025.
  • The International Prix Galien Award is presented biennially to honor the "best of the best" in medical innovation, often regarded as the biopharmaceutical equivalent of the Nobel Prize.
  • The award was founded 50 years ago in France by Roland Mehl to recognize efforts advancing medical science.